The plant-based refers to plant-based raw materials or products that are available as the source of protein and fat. Utilization and development of walnuts as a plant-based, resulting in a high-quality protein-rich walnut plant-based product: walnut protein powder and walnut peptides. Progress in research on the application of walnuts as a plant-based has been advanced, solving the problem of wasted resources and environmental pollution caused by the fact that walnut residue, a product of walnuts after oil extraction, is often thrown away as waste, or becomes animal feed or compost. This paper reviews and summarizes the research and reports on walnut plant-based at home and abroad, focusing on the application of walnut plant-based in the preparation process (enzymatic and fermentation methods) and the biological activity of the walnut protein and walnut peptide, to provide a theoretical basis for the further processing of walnuts as a walnut plant-based. It can make full use of walnut resources and play its nutritional and health care value, develop and build a series of walnut plant-based products, improve the competitiveness of walnut peptide products, turn them into treasure, and provide more powerful guidance for the development of food and medicine health industry in Yunnan.

Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study

Febrile neutropenia (FN) is a serious complication in patients with hematologic malignancies following treatments such as chemotherapy and hematopoietic stem cell transplantation. It is typically managed with broad-spectrum antibiotics (BSA), but the optimal duration of BSA therapy remains controversial. This meta-analysis aimed to assess the clinical efficacy and safety of early antibiotic de-escalation in patients with hematologic malignancies with FN before hematopoietic recovery, compared to those who continued BSA until hematopoietic recovery. Statistical analysis included pooled odds ratios (OR) for mortality and secondary adverse outcomes, along with subgroup analysis to identify patient populations that may benefit from early de-escalation. Ten studies, mostly retrospective observational designs, were included. Early de-escalation significantly reduced mortality risk (OR 0.20, 95% CI 0.06–0.69). Subgroup analyses showed mortality benefits in older patients (>55 years old, OR 0.42, 95% CI 0.18–0.98) and in higher-quality studies (OR 0.07, 95% CI 0.01–0.62). No significant differences were observed for infection-related ICU admissions, bacteremia, recurrent fever, or Clostridium difficile infection (CDI). In conclusion, early de-escalation of BSA in patients with hematologic malignancies and developing FN after treatment significantly reduces mortality risk without increasing major adverse events. These findings support the use of early de-escalation and highlight the need for personalized strategies to improve patient outcomes.

While high-dose therapy and autologous stem cell transplant (ASCT) remain integral to the primary treatment of newly diagnosed transplant-elble multiple myeloma (MM) patients, the challenge of disease progression persists. The primary objective of this meta-analysis is to evaluate the efficacy and safety of tandem ASCT compared to single ASCT. We conducted a systematic review and meta-analysis of randomized controlled trials and observational studies comparing tandem ASCT with single ASCT in patients with newly diagnosed MM. We searched PubMed, EMBASE, Cochrane Library, and Clinical Trials databases for studies published up to January 2024. The primary outcomes were progression-free survival (PFS), overall survival (OS), overall response rate (ORR), complete response rate (CRR), and treatment-related mortality (TRM). We used a random-effects model to calculate pooled hazard ratios (HRs) and relative risks (RRs) with 95% confidence intervals (CIs). Study quality was assessed using the Cochrane risk of bias tool and Newcastle–Ottawa Scale. Twelve studies involving 5057 patients met the inclusion criteria. Tandem ASCT was associated with a significantly higher CRR compared to single ASCT (HR 1.33, 95% CI 1.03–1.71, I2 = 15%), but no significant differences were observed in PFS (HR 0.75, 95% CI 0.42–1.34, I2 = 14%), OS (HR 0.60, 95% CI 0.33–1.10, I2 = 27%), or the ORR (RR 0.80, 95% CI 0.59–1.08, I2 = 33%). However, tandem ASCT was associated with a significantly higher risk of TRM (RR 1.78, 95% CI 1.00–3.18, I2 = 0%). Tandem ASCT improves the CRR but does not provide significant benefits in terms of PFS, OS, or ORR compared to single ASCT in patients with newly diagnosed MM. Moreover, tandem ASCT is associated with a higher risk of TRM. The decision to pursue tandem ASCT should be made on an individual basis, carefully weighing the potential benefits and risks in light of each patient’s unique clinical situation. Future research should focus on identifying patient subgroups most likely to benefit from tandem ASCT and exploring strategies to optimize the efficacy and safety of this approach in the context of novel agent-based therapies.

Introduction: Brain tumors pose significant diagnostic and therapeutic challenges due to their diverse treatment responses and complex imaging characteristics. Traditional MRI techniques often struggle to differentiate between tumor recurrence and post-treatment changes such as pseudoprogression and necrosis, highlighting the need for more accurate diagnostic tools. Material and Methods: This retrospective study conducted at a single tertiary care center and evaluated the diagnostic efficacy of Treatment Response Assessment Maps (TRAMs), also known as Contrast Clearance Analysis (CCA), in distinguishing between tumor recurrence and post-treatment changes in patients who underwent initial treatment for brain tumors. Data from 27 patients were analyzed, including 10 who underwent surgical resection (Group 1) and 17 who had serial images and TRAMs/CCA assessment (Group 2). Result: In Group 1, TRAMs/CCA demonstrated nine positive results, with 8 cases of tumor recurrence confirmed via biopsy. A biopsy also confirmed one negative result after a discussion with the patient. In Group 2, where patients did not undergo biopsy, TRAMs/CCA results varied but correlated with clinical outcomes, underscoring the potential utility of TRAMs/CCA in guiding treatment decisions. These findings suggest that TRAMs/CCA may have superior diagnostic performance compared to traditional MRI in differentiating between tumors. Conclusion: TRAMs/CCA represents a promising advancement in the imaging assessment of brain tumor treatment response, offering higher sensitivity than conventional MRI methods. While implementing TRAMs/CCA could potentially improve diagnostic accuracy and optimize therapeutic strategies for patients with brain tumors, the final decision remains highly dependent on patient-centered discussions.